CD274 and cancer: The selective inhibition of the PD1/PD-L1 interaction is expected to maintain the host defense system and contribute to cancer eradication11, including urothelial bladder cancer12, non-small-cell lung cancer13, hepatocellular carcinoma14, skin cutaneous melanoma15,16, and mucosal melanoma17,18.